Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer

Summary

This study provides compassionate use of bicalutamide (Casodex) at a 150-mg dose for subjects with prostate cancer prior to it becoming commercially available. The patient will receive bicalutamide 150-mg as long as the physician feels that the subject is benefiting from this therapy and safety information is provided regularly to AstraZeneca. Treatment will be discontinued after bicalutamide 150-mg becomes commercially available.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications